BTIG Maintains Buy on CymaBay Therapeutics, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Julian Harrison maintains a Buy rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $15 to $18.
July 05, 2023 | 9:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Julian Harrison maintains a Buy rating on CymaBay Therapeutics and raises the price target from $15 to $18.
The news is directly related to CymaBay Therapeutics. The maintained Buy rating and increased price target by BTIG analyst Julian Harrison indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100